Literature DB >> 10693071

Personal exposure to atmospheric polycyclic aromatic hydrocarbons in a general adult population and lung cancer risk assessment.

D Zmirou1, P Masclet, C Boudet, F Dor, J Déchenaux.   

Abstract

Personal exposure to nine particulate-phase atmospheric polycyclic aromatic hydrocarbons (PAHs) was assessed among adult non-smoking volunteers in the Grenoble, France, metropolitan area. Using Toxic Equivalency Factors, the associated total atmospheric PAHs lifelong cancer risk was estimated. For 48 hours continuously, 38 subjects without specific occupational exposure to combustion sources carried a PM2.5 particles personal exposure monitor while at home, at work, commuting, or involved in other activities. One phase of the study took place in summer; a second in winter. The monitor set was composed of a pump with an airflow of 4 L.mn-1, a 2.5-micron cyclone, and Teflon filters. The PAH concentrations were determined on seven PM2.5 filters by using high performance liquid chromatography with fluorimetric detection. The predominant PAHs are fluoranthene and indeno pyrene. According to the compound, the personal exposure estimates ranged from 0.13 to 1.67 ng/m3 (yearly means). The average benzo(a) pyrene value is 0.67 ng/m3 (95% confidence interval = 0 to 2.1 ng/m3). Winter exposures were 3 to 25 times greater than summer exposures. The total PAHs lung cancer lifelong risk is 7.8 10(-5) and is driven by exposure to benzo(a) pyrene. Although these risk estimates are 2 to 3 orders of magnitude lower than those associated with specific occupational exposures in the coal or smelter industries, they are of public health concern because they are spread over large urban populations. Further personal exposure studies in adult or children populations are needed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693071     DOI: 10.1097/00043764-200002000-00004

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  6 in total

1.  The sociobiologic integrative model (SBIM): enhancing the integration of sociobehavioral, environmental, and biomolecular knowledge in urban health and disparities research.

Authors:  M Chris Gibbons; Malcolm Brock; Anthony J Alberg; Thomas Glass; Thomas A LaVeist; Stephen Baylin; David Levine; C Earl Fox
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

2.  Ambient concentrations and personal exposure to polycyclic aromatic hydrocarbons (PAH) in an urban community with mixed sources of air pollution.

Authors:  Xianlei Zhu; Zhihua Tina Fan; Xiangmei Wu; Kyung Hwa Jung; Pamela Ohman-Strickland; Linda J Bonanno; Paul J Lioy
Journal:  J Expo Sci Environ Epidemiol       Date:  2011-03-02       Impact factor: 5.563

3.  Multidrug resistance protein (MRP) 4 attenuates benzo[a]pyrene-mediated DNA-adduct formation in human bronchoalveolar H358 cells.

Authors:  Stacy L Gelhaus; Oren Gilad; Wei-Ting Hwang; Trevor M Penning; Ian A Blair
Journal:  Toxicol Lett       Date:  2011-11-30       Impact factor: 4.372

4.  Biomarkers of oxidative stress and its association with the urinary reducing capacity in bus maintenance workers.

Authors:  Jean-Jacques Sauvain; Ari Setyan; Pascal Wild; Philippe Tacchini; Grégoire Lagger; Ferdinand Storti; Simon Deslarzes; Michel Guillemin; Michel J Rossi; Michael Riediker
Journal:  J Occup Med Toxicol       Date:  2011-05-30       Impact factor: 2.646

5.  Predictors of personal polycyclic aromatic hydrocarbon exposures among pregnant minority women in New York City.

Authors:  Cathryn C Tonne; Robin M Whyatt; David E Camann; Frederica P Perera; Patrick L Kinney
Journal:  Environ Health Perspect       Date:  2004-05       Impact factor: 9.031

6.  An integrated approach to assess exposure and health-risk from polycyclic aromatic hydrocarbons (PAHs) in a fastener manufacturing industry.

Authors:  Hsin-I Hsu; Ming-Yeng Lin; Yu-Cheng Chen; Wang-Yi Chen; Chungsik Yoon; Mei-Ru Chen; Perng-Jy Tsai
Journal:  Int J Environ Res Public Health       Date:  2014-09-15       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.